$DFTX News

Definium Therapeutics, Inc. (DFTX) Discusses Phase III Clinical Progress and Study Outcomes for Lead Program in Mood Disorders Transcript

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

B of A Securities Initiates Coverage On Definium Therapeutics with Buy Rating, Announces Price Target of $75

Maxim Group Maintains Buy on Definium Therapeutics, Raises Price Target to $55

Definium Therapeutics (DFTX) Voyage Data Puts Valuation Back In Focus

Is Successful Voyage Phase 3 Data Transforming the Investment Case For Definium Therapeutics (DFTX)?

Definium Therapeutics (DFTX) Hits Phase 3 GAD Goals For DT120 ODT

Definium Therapeutics' DT120 Data Boosts Confidence in Future Trials, RBC Capital Markets Says

Jones Trading Maintains Buy on Definium Therapeutics, Raises Price Target to $90

Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $64

RBC Capital Maintains Outperform on Definium Therapeutics, Raises Price Target to $66

Definium Therapeutics’ DT120 Meets Phase III Goals in GAD Study

Wells Fargo Maintains Overweight on Definium Therapeutics, Raises Price Target to $72

Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $75

Definium Scores Another Win For Its LSD-Based Drug. Shares Pop.

Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Generalized Anxiety Disorder Transcript

Definium Therapeutics: 'Strong Buy' On Positive DT120 ODT Data, Two Indications, And September 2026 Catalyst

DFTX Stock Rallies As Psychedelic Drug Delivers Positive Anxiety Trial Results — Retail Says DT120 Could ‘Disrupt The Market’

Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Generalized Anxiety Disorder - Slideshow